Minocycline inhibits smooth muscle cell proliferation, migration and neointima formation after arterial injury

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 4, 2003, Pages 469-476

  Pinney, Sean P ^b   Chen, Hong Jun ^b   Liang, Daxing ^b   Wang, Xiangyuan ^b   Schwartz, Allan ^b   Rabbani, LeRoy E ^a  

^a Herbert Irving Pavilion ^*  (United States)

^b NONE

Author keywords

Arterial injury; Metalloproteinases; Minocycline; Restenosis; Vascular smooth muscle

Indexed keywords

GELATINASE A; MATRIX METALLOPROTEINASE; MINOCYCLINE; POLOXAMER; TETRACYCLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY INJURY; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GEL; HUMAN; HUMAN CELL; LETHALITY; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

ANGIOPLASTY, BALLOON; ANIMALS; CAROTID ARTERY INJURIES; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; HUMANS; MALE; MATRIX METALLOPROTEINASES; MINOCYCLINE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; TUNICA INTIMA;

EID: 0141642017     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200310000-00003     Document Type: Article

References (27)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature. 1993;362:801-809.
2. Brenner CA, Adler RR, Rappolee DA, et al. Genes for extracellular-matrix-degrading metalloproteinases and their inhibitor, TIMP, are expressed during early mammalian development. Genes Dev. 1989;3:848-859.
3. Pauly RR, Passaniti A, Bilato C, et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994;75:41-54.
4. Bendeck MP, Zempo N, Clowes AW, et al. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
5. Clowes AW, Clowes MM, Au YPT, et al. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 1990;67:61-67.
6. Liu MW, Roubin GS, King SB. Restenosis after coronary angioplasty: potential biologic determinants and role of intimal hyperplasia. Circulation. 1989;79:1374-1387.
7. Southgate KM, Fisher M, Banning AP, et al. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res. 1996;79:1177-1187.
8. Zempo N, Kenagy RD, Au YP, et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg. 1994;20:209-217.
9. Southgate KM, Davies M, Booth RF, et al. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J. 1992;288:93-99.
10. Smilack JD. The tetracyclines. Mayo Clin Proc. 1999;74:727-729.
11. Bendeck MP, Conte M, Zhang M, et al. Doxycycline modulates smooth muscle cell growth, migration and matrix remodeling after arterial injury. Am J Pathol. 2002;160:1089-1095.
12. Nip LH, Uitto V-J, Golub LM. Inhibition of epithelial cell matrix metalloproteinases by tetracyclines. J Periodontal Res. 1993;28:379-385.
13. Uitto V-J, Firth JD, Nip L, et al. Doxycycline and chemically modified tetracyclines inhibit Gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann N Y Acad Sci. 1994;732:140-151.
14. Greenwald RA, Moak SA, Ramamurthy NS, et al. Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol. 1992;19:927-938.
15. Yang Z, Noll G, Luscher TF. Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation. 1993;88:832-836.
16. Ferns GAA, Raines EW, Sprugel KH, et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
17. Jackson CL, Reidy MA. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann N Y Acad Sci. 1992;667:141-150.
18. Krane SM. Clinical importance of metalloproteinases and their inhibitors. Ann N Y Acad Sci. 1994;732:1-10.
19. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays. 1992;14:455-463.
20. Webb KE, Henney AM, Anglin S, et al. Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. Arterioslcer Thromb Vasc Biol. 1997;17:1837-1844.
21. Cheng L, Mantile G, Pauly R, et al. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation. 1998;98:2195-2201.
22. Yanagi H, Sasaguri Y, Sugama K, et al. Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis. 1991;91:207-216.
23. Kaufmann D, Pichler W, Beer JH. Severe episode of high fever with rash, lymphadenopathy, neutropenia, and eosinophilia after minocycline therapy for acne. Arch Intern Med. 1994;154:1983-1984.
24. Davies MG, Kersey PJ. Acute hepatitis and exfoliative dermatitis associated with minocycline. BMJ. 1989;298:1523-1524.
25. Wang W, Chen HJ, Schwartz A, et al. Sequence independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorthioate oligodeoxynucleotides. J Clin Invest. 1996;98:443-450.
26. Wang W, Chen HJ, Sun J, et al. A comparison of gunosine-quartet inhibitory effects versus cytidine homopolymer inhibitory effects on rat neointimal formation. Antisense Nucleic Acid Drug Dev. 1998;8:227-236.
27. Tolomeo M, Grimaudo S, Milano S, et al. Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines. Br J Pharmacol. 2001;133:306-314.